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3 Abstract:
We have previously reported on the unusual h5-HT 7 receptor inactivating properties of risperidone, 9-OHrisperidone, bromocryptine, methiothepin, metergoline, and lisuride (Smith et al., 2006; Knight et al., 2009) . Inactivation was defined as the inability of 10µM 5-HT to stimulate cAMP accumulation after brief exposure and thorough removal of the drugs from HEK293 cells expressing h5-HT 7 receptors.
Herein we report that brief exposure of the h5-HT 7 receptor-expressing cells to inactivating drugs, followed by removal of the drugs, results in potent and efficacious irreversible inhibition of forskolinstimulated adenylate cyclase activity. Pre-treatment, followed by removal of the inactivating drugs inhibited 10µM forskolin-stimulated adenylate cyclase activity with potencies similar to the drugs' affinities for the h5-HT 7 receptor. The actions of the inactivating drugs were pertussis toxin-insensitive, indicating the lack of G i in their mechanism(s) of action. Methiothepin and bromocryptine maximally inhibited 10µM forskolin-stimulated adenylate cyclase while the other drugs produced partial inhibition, indicating the drugs are inducing slightly different inactive conformations of the h5-HT 7 receptor.
Maximal effects of these inactivating drugs occurred within 15-30 min of exposure of the cells to the drugs. A G s -mediated inhibition of forskolin-stimulated activity has never been reported. The inactivating antagonists appear to induce a stable conformation of the h5-HT 7 receptor, which induces an altered state of G s , which, in turn, inhibits forskolin-mediated stimulation of adenylate cyclase . These and previous observations indicate the inactivating antagonists represent a unique class of drugs and may reveal GPCR regulatory mechanisms previously unknown. These drugs may produce innovative approaches to the development of therapeutic drugs.
Introduction:
The 5-HT 7 receptor is one of 14 5-HT receptors expressed in mammalian tissues (Teitler and Herrick-Davis, 1994; Gerhardt and van Heerikhuizen, 1997; Hoyer and Martin, 1997; Hoyer et al., 2002; Kroeze et al., 2002; Raymond et al., 2001) . It was discovered through homology cloning and is expressed in various areas of the human brain and in peripheral tissues, including important blood vessels in the cerebral vasculature (Bard et al., 1993; Lovenberg et al., 1993; Shen et al., 1993; Teitler and HerrickDavis, 1994; Hedlund and Sutcliffe, 2004) . 5-HT 7 receptor antagonists are being developed for possible use in various clinical conditions including migraine (Terron, 1997) , sleep (Lovenberg et al., 1993) , psychosis (Bard et al., 1993; Lovenberg et al., 1993; Shen et al., 1993) , and depression (Bard et al., 1993; Lovenberg et al., 1993; Shen et al., 1993; Hedlund and Sutcliffe, 2004) .
Risperidone is a highly prescribed atypical antipsychotic drug (Love and Nelson, 2000; Bhana and Spencer, 2000; Green, 2000; Schneider et al., 2006) . It is one of a group of drugs believed to initiate their effects through interactions with the D 2 dopamine and 5-HT 2A serotonin receptors (Roth et al., 1994; Meltzer et al., 1989) . These interactions have been shown to be classical competitive antagonist interactions (Smith et al., 2006; Roth et al., 1994) . In previous publications, using h5-HT 7 receptorexpressing HEK293 cells, we reported the rapid, potent inactivation of h5-HT 7 receptor stimulation of cAMP production by six antagonists: risperidone, 9-OH-risperidone, methiothepin, bromocryptine, metergoline and lisuride (Smith et al., 2006; Knight et al., 2009) . The mechanism appears to involve the pseudo-irreversible interaction of the drugs with the h5-HT 7 receptor, thus occluding the orthosteric binding site and preventing stimulation by 5-HT.
However, several observations indicated a simple pseudo-irreversible blockade might not fully explain the effect of the inactivating antagonists. Risperidone and 9-OH-risperidone irreversibly inhibited only 50% of the h5-HT 7 orthosteric binding sites, while the four other inactivators irreversibly inhibited This article has not been copyedited and formatted. The final version may differ from this version. all the h5-HT 7 receptor binding sites (Knight et al., 2009) . Also, metergoline's potency as an inactivator was significantly lower than predicted from its affinity for the h5-HT 7 receptor, while the other five inactivators' potencies matched their affinities for the h5-HT 7 receptor.
The effects of forskolin on adenylate cyclase activity have been extensively studied (Stengel et al., 1982; Darfler et al., 1982; Insel and Ostrom, 2003; Alousi et al., 1991; Dessauer et al., 1997; Tang and Gilman, 1995) . While the major effect of forskolin is to directly stimulate adenylate cyclase activity, this stimulation can be regulated by GPCRs through G-proteins (Tesmer et al., 2002; Taussig et al., 1993; Bender et al., 1984; Neer, 1986; Neer, 1978) . The predominant regulation of forskolin-stimulated adenylate cyclase activity is mediated by activation of Gi/o-coupled GPCR which partially inhibit forskolin-stimulated adenylate cyclase activity (Tesmer et al., 2002; Taussig et al., 1993; Bender et al., 1984; Neer, 1986; Neer, 1978) . It has been reported that agonist-mediated modulation of forskolinstimulated adenylate cyclase can be produced through G s -coupled receptors (Stengel et al., 1982) . This effect is relatively minor and usually manifests as a potentiation of forskolin-stimulated activity. It should be noted that the GPCR-mediated regulation of forskolin-stimulated adenylate cyclase activity occurs through activity of agonists on GPCR. There appears to be no reports of acute effects of antagonists on forskolin-stimulated adenylate cyclase activity. While conducting the studies previously reported (Knight et al., 2009) , forskolin-stimulated adenylate cyclase activity was routinely monitored as a control for the status of cellular adenylate cyclase activity. It was anticipated that forskolin-stimulated adenylate cyclase activity would not be affected by the inactivating drugs. As described below, the inactivating antagonists produced unique effects on h5-HT 7 receptor activity, demonstrated by the persistent inhibition of forskolin-stimulated cAMP in cells exposed to this novel group of drugs. These effects provide significant information concerning the mechanism by which the inactivating antagonists produce their effects on h5-HT 7 receptor-mediated cAMP production. This article has not been copyedited and formatted. The final version may differ from this version. cAMP Assay: Total cAMP accumulation was measured using the LANCE cAMP Detection kit (PerkinElmer). Cells were cultured for 18 hrs in serum-free media, with and without 100ng/ml pertussis toxin (see Results, figure 1). Cells were lifted using 1ml/dish diluted Versene (1:3 in PBS), followed by the addition of 11ml/dish HEPES buffer (20mM HEPES, 2.5mM MgSO4, 134mM NaCl, pH 7.5 at 23 o C).
Cells were centrifuged for 3 min at 330×g, supernatant was aspirated and the cells were resuspended in HEPES buffer. Cells were pre-treated with drug, incubated 30 min at 37°C (or 15, 30, 60, and 90 min for time-course experiments), washed 3×10 min in HEPES buffer. After the third wash, cells were resuspended in stimulation buffer (prepared according to the Perkin-Elmer LANCE cAMP instruction manual). Cells were counted with a hemacytometer and added to 96-well white opaque plates. The pretreated cells were then exposed to 10µM or 35µM forskolin for 30 min at 23°C. Detection buffer was then added (prepared according to the LANCE instruction manual, Perkin-Elmer). Control experiments demonstrated that this procedure produced no effect on the cells' responsiveness to forskolin (see Results) .
Control experiments also demonstrated that performing the forskolin stimulation at 37 o C has no effect on the properties of the inactivating antagonists (see Results). Time-resolved fluorescence resonance energy transfer was detected by the Victor3 1420 plate-reader (Perkin-Elmer).
Risperidone and metergoline pre-treatment experiments: Cells were lifted and centrifuged as above. properties. These drugs were selected based on preliminary radioligand binding studies indicating they had high to moderate affinities for the h5-HT 7 receptor. The h5-HT 7 receptor expressing HEK293 cells were first exposed to 1µM drug for 30 minutes, followed by three washouts. The cells were then exposed to 10µM forskolin for 30 minutes. Inactivation was defined as the inability, or a reduced ability, of the cells to produce cAMP in response to forskolin stimulation after the thorough washout of drug. Six of the drugs tested displayed this property: risperidone, 9-OH-risperidone, methiothepin, bromocryptine, metergoline, and lisuride. These six drugs had been previously characterized as h5-HT 7 receptor inactivators (Smith et al., 2006; Knight et al., 2009 ). The six drugs tested that had inactivating ability exhibited h5-HT 7 receptor affinities that ranged from 0.4nM-143nM. Lisuride, (0.4nM), risperidone (2nM), methiothepin (3nM), 9-OH-risperidone (10nM), metergoline (16nM), and bromocryptine (143nM) displayed inactivating properties ( figure 1A ). Other drugs tested that did not display inactivating properties are listed with their h5-HT 7 receptor affinities (nM) :amoxapine (69); amitriptyline (96); cyproheptadine (24); loxapine (258); mianserin (64); ritanserin (468); the selective 5-HT 7 receptor antagonist SB269970 (2); tenilapine (153); TFM (1624); trifluperazine (497); the high affinity 5-HT 2 receptor antagonist ICI169369 (393); clozapine (30); methysergide (32) and LSD (3). Of the six inactivators methiothepin and bromocryptine appeared to produce the most efficacious inhibition of 10µM forskolin-stimulation (figures 1). In order to determine if the h5-HT 7 receptor might be stimulating a G i , thereby inhibiting forskolin-stimulated adenylate cyclase activity, we pre-treated the h5-HT 7 -receptor expressing cells with pertussis toxin, which inactivates G i (Kaslow et al., 1987) . Although the h5-HT 7 receptor is a well-characterized G s -coupled receptor, it is possible that the "inactivating antagonists" are inducing a persistent state of the receptor that stimulates G i , thereby inhibiting forskolinThis article has not been copyedited and formatted. The final version may differ from this version. indicate that six out of twenty drugs tested produced the inactivating effect on forskolin-stimulated adenylate cyclase activity, this effect is mediated through the h5-HT 7 receptor rather than through a nonspecific mechanism, and the effect is not due to some temperature-induced alteration in the assay conditions.
In order to obtain more information on this novel ability to irreversibly inhibit forskolin-stimulated adenylate cyclase activity, concentration-response curves for the inactivating effect were produced ( figure   3 ; table 1). The h5-HT 7 receptor expressing HEK293 cells were first exposed to increasing concentrations of drug for 30 minutes, followed by three washouts. The cells were then exposed to 10 or 35µM forskolin for 30 minutes. Risperidone, 9-OH-risperidone, bromocryptine, methiothepin, metergoline and lisuride (table 2) . Methiothepin and bromocryptine irreversibly inhibit forskolin-stimulated activity more effectivly than risperidone, 9-OH-risperidone, metergoline or lisuride. These results indicate the possibility of either one mechanism with multiple efficacies among the inactivating drugs (full and partial inactivators), or multiple mechanisms of inhibition among the inactivating drugs. The major observation was that methiothepin and bromocryptine are fully efficacious in irreversibly inhibiting forskolinstimulated adenylate cyclase activity, while the other four inactivating drugs display less efficacy.
In order to determine if the difference in efficacies could be due to kinetic differences between the drugs in producing the inactivating effect, time-course experiments were performed (figure 4). Cells were pre-treated with each of the inactivators for 15, 30, 60, and 90 minutes and then subjected to the usual washout and assay procedures (described above). While several interesting observations were made in these experiments (see Discussion) it is clear that the lower efficacy of risperidone, 9-OH-risperidone, metergoline and lisuride, relative to methiothepin and bromocryptine, cannot be due to slower kinetics.
The lesser effect observed for several of the drugs at the 90 min time point is contrary to this possibility.
Another possible rationale for the difference in efficacies could be different mechanisms involving distinct sites on the h5-HT 7 receptor mediating the effects of the inactivators. In order to obtain information on this possibility, h5-HT 7 receptor expressing cells were exposed to 10µM metergoline or risperidone (partial inactivators) for 30 minutes, washed, and then exposed to 10µM methiothepin or bromocryptine (full inactivators). Metergoline and risperidone were chosen based on previous observations indicating they display somewhat different properties as inactivators (Knight et al., 2009) .
As shown in figure 5A , pre-treatment with metergoline resulted in a blunting of the effect of bromocrytpine but had no effect on methiothepin's inactivating activity. Risperidone pre-treatment had no This clozapine, methiothepin or risperidone. None of the drugs produced any effect on the levels of adenylate cyclase or G s , indicating that the loss of activity subsequent to inactivating drug treatment is not due to some dramatic effect on the cellular levels of these signal transduction components.
Discussion:
The results presented herein continue a series of unusual observations involving the h5-HT 7 receptor (Smith et al., 2006; Knight et al., 2009) . Six drugs out of a total of 20 drugs that have been tested produce an irreversible inactivation of the h5-HT 7 receptor, as judged by inhibition of 10µM 5-HT stimulation of cAMP production. A pseudo-irreversible interaction between the "inactivating drugs" and the h5-HT 7 receptor appears to be the cause of this unusual effect (Smith et al., 2006) . Five of the drugs appear to produce a complete inhibition of 5-HT stimulated receptor activity, with the possible exception of metergoline (Knight et al., 2009) . The pseudo-irreversible block of the orthosteric binding site on the h5-HT 7 receptor appears to explain the inactivation of the receptor. However it was also noted that risperidone and 9-OH-risperidone, which potently and fully inactivate 5-HT stimulated h5-HT 7 receptor, only irreversibly block 50% of the binding sites (Knight et al., 2009 ). This observation indicates that receptor occupancy is not sufficient to fully predict the effect of the inactivators on the h5-HT 7 receptor This article has not been copyedited and formatted. The final version may differ from this version. activity. These results indicated that risperidone and 9-OH-risperidone, while producing a pseudoirreversible complex with the h5-HT 7 receptor, might be, in addition, interacting with the h5-HT 7 receptor in a somewhat different manner than the other four inactivators.
In the present study another unusual observation is described. Forskolin-stimulated adenylate cyclase activity is due to the direct interaction of forskolin with all the isoforms of adenylate cyclase, except for the ram sperm form of the enzyme (Alousi et al., 1991) . The interaction of activated G s appears to have a secondary influence on the ability of forskolin to stimulate adenylate cyclase (Tesmer et al., 2002; Taussig et al., 1993; Bender et al., 1984; Neer, 1986; Neer, 1978) . A more pronounced inhibitory influence of G i -coupled receptors on forskolin-stimulated adenylate cyclase is a well-documented cellular mechanism (Mons and Cooper, 1995) . However the involvement of G i in the current study has been eliminated, as pertussis toxin, an irreversible inhibitor of G i , has no effect on the inactivating properties of drugs presented (figure 1). Agonist stimulation of receptors, acting through GTP-binding proteins, have been shown to slightly increase forskolin-stimulated adenylate cyclase activity (Darfler et al., 1982; Insel and Ostrom, 2003; Alousi et al., 1991) . Antagonist-induced inhibition of forskolin-stimulated adenylate cyclase is a novel observation. The irreversible effects of the six inactivating drugs on forskolinstimulated adenylate cyclase activity, particularly that of methiothepin and bromocryptine, are unprecedented. Furthermore these results indicate that the inactivating drugs, particularly methiothepin and bromocryptine, must be doing more than simply irreversibly occluding the orthosteric binding site on the h5-HT 7 receptor. The effects on forskolin-stimulated adenylate cyclase suggest that the inactivators are inducing a stable, persistent, inactive state of the h5-HT 7 receptor that, in turn, is inducing an inactive state of G s . The inactive G s must be inducing a state of adenylate cyclase with less than maximal forskolin-stimulated potential. In other words, the effects on forskolin-stimulated activity observed reveal several things about the receptor inactivating mechanism of these drugs. First, the inactivators irreversibly induce a state of the receptor that inactivates G s , eliminating the receptor-mediated cAMP stimulation as previously reported (Smith et al., 2006; Knight et al., 2009) . Second, the G s /adenylate cyclase interaction may be altered, inhibiting forskolin's ability to stimulate adenylate cyclase. The similar potencies of the inactivating drugs on 10 or 35µM forskolin-stimulated activity ( figure 3, table 1) indicates the mechanism-of-action is not a competitive one. The maximal degree of irreversible inhibition of forskolinstimulation varies amongst the different inactivators and is not predicted by maximal receptor occupancy (see Knight et al., 2009) .
In order to determine the possibility that the lower maximal effect of metergoline was due to a slower onset of effect, time course experiments were performed (figure 4). Overall, the effect of The results in figure 5B , demonstrating that risperidone pre-treatment is ineffective in blunting the effects of either bromocryptine or methiothepin, are also notable. These results are consistent with previous results indicating that risperidone's mechanism of action is different than metergoline's (Knight et al., 2009 ). Risperidone and 9-OH-risperidone have been shown to completely inactivate the h5-HT 7 receptor, while irreversibly blocking 50% of the receptors, while metergoline irreversibly blocks all the h5-HT 7 receptors and produces a profound inactivation of the h5-HT 7 receptor. The results in figure 4 reinforce the possibility of a different mechanism-of-action between risperidone and metergoline. Thus figure 4 indicates methiothepin, bromocryptine, risperidone, and metergoline differ in their interactions with the h5-HT 7 receptor, as judged by forskolin-stimulated adenylate cyclase activity. The details of these differences are under investigation.
The results presented herein and in the two previous papers (Smith et al., 2006; Knight et al., 2009 ) are highly unusual and unprecedented. However there has been a published paper (Krobert et al., 2006) that reports similar effects with four drugs used in our studies. In this report the authors found that while mesulergine, SB269970, and clozapine produced little or no effect on the levels of 3 H-5-CT-labeled h5-HT 7 receptors after removal of the drugs, methiothepin reduced binding levels by 79%, with no change in affinity for the radioligand. These results correspond with the results we have reported previously: methiothepin inactivates the h5-HT 7 receptor and inhibits 3 H-5-HT labeling of the h5-HT 7 receptor after This article has not been copyedited and formatted. The final version may differ from this version. removal: mesulergine, SB269970 and clozapine do not produce these effects (Smith et al., 2006; Knight et al., 2009 ). We have not found any other studies that studied the 5-HT 7 receptor after removal of drugs.
The findings displayed in these studies, and in the previous papers {1,426} indicate that the h5- In summary, the results presented add another novel observation concerning the effects of inactivating drugs on the h5-HT 7 receptor, through what appears to be a pseudo-irreversible complex (Smith et al., 2006; Knight et al., 2009) inactivating drugs appear to possess properties that produce effects on GPCRs that are distinct from competitive antagonists and thus may lead to the discovery of novel GPCR regulatory mechanisms. These novel regulatory mechanisms may be targets for the development of novel therapeutic drugs.
. This article has not been copyedited and formatted. The final version may differ from this version. Figure 1 : A: Effect of drug pre-treatment on 10µM forskolin-stimulated cAMP production by HEK 293 cells stably expressing h5-HT 7 receptors, and the lack of effect of pertussis toxin on the drug effects. Cells were cultured for 18hr in serum-free media in the absence and presence of 100 ng/ml pertussis toxin.
Cells were suspended in HEPES buffer and exposed to a 10µM concentration of drugs for 30 min. Cells were gently pelleted, and resuspended in HEPES buffer and incubated at 37 B: Drugs displaying no effect on forskolin-stimulated adenylate cyclase activity after thorough washout.
The results are the means ± SEM of three independent experiments performed in triplicate. There was no significant effect observed with these drugs (p=.12, one-way ANOVA). minutes, and thoroughly washed. After the drug washout procedure (see Materials and Methods) the cells were exposed to 10µM forskolin, and cAMP was detected as described above. Results are the means ±SEM of three independent experiments. Metergoline blunted the effects of bromocryptine (p<0.001) but had no effect on methiothepin's activity. Risperidone had no significant effect on methiothepin or bromocryptine (see Discussion). h5-HT 7 -receptor expressing cells were exposed to 10µM drugs for 30 min, thoroughly washed, then exposed to 10 or 35µM forskolin for 30 min (see figure three) . The values listed are the percentage of forskolin-stimulated activity observed in cells not exposed to inactivators. cAMP was detected using the LANCE kit (see Materials and Methods 
